Genentech, Inc.

Maxygen, Inc.

Indiana University

F. Hoffmann-la Roche Ag

Steven R Leong

Yan Wu

Wei-Ching Liang

Andrew G Polson

Zahra Shahrokh

Iphigenia Koumenis

Vanessa Hsei

Gerardo A Zapata

Leonard G Presta

Paul Polakis

Ron Firestein

Sherman Fong

Kyung Jin Kim

Juha Punnonen

Caroline Alice Hebert

Tania N Gonzalez

Mark S Dennis

Robert F Kelley

Allen J Ebens

Bing Zheng

Xiaocheng Chen

Shang-Fan Yu

Cecilia Pui Chi Chiu

Mary A Mathieu

Alexandra L L Lazetic

Chia-Chun Chang

Claire M Doerschuk

Alexandra Lazetic

Jean Chia-Chun Chang

Gerarado A Zapata

Mary Mathieu

Wei-Chang Liang

Wei -Ching Liang

The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.

Anti-B7-H4 antibodies and immunoconjugates

The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.

Anti-CLL-1 antibodies and methods of use

The invention provides anti-CD33 antibodies and immunoconjugates and methods of using the same.

Anti-CD33 antibodies and immunoconjugates

The disclosure provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.

Described are conjugates formed by an antibody fragment covalently attached to a nonproteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-&#x3b1; (TNF-&#x3b1;), human tissue factor (TF), human &#x3b1;&#x3b2;integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor &#x3b1;-chain (TAC) for diagnostic and therapeutic applications.

Methods of binding TNF-&#x3b1; using anti-TNF-&#x3b1; antibody fragment-polymer conjugates

Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-&#x3b1; (TNF-&#x3b1;), human tissue factor (TF), human &#x3b1;&#x3b2;integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor &#x3b1;-chain (TAC) for diagnostic and therapeutic applications.

Antibody fragment-polymer conjugates and uses of same

The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.

Co-stimulatory polypeptides

Growing community of inventors

Berkeley, CA, United States of America

Steven R Leong